Mediverify Database
.png)
.png)
Welcome to the official website of the National Medicine Regulatory Authority of Sri Lanka. We are dedicated to ensuring the safety and efficacy of medicines for the people of Sri Lanka.
The National Medicine Regulatory Authority of Sri Lanka is committed to ensuring the safety, efficacy, and quality of medicines in the country. We strive to protect public health by regulating the manufacturing, importation, distribution, and sale of medicines.
NMRA regulates medicines, medical devices, borderline products imported to and manufactured in Sri Lanka. We also regulate pharmacies. Clinical trials conducted in Sri Lanka are also regulated by us.
Find Out MoreNational Medicines Quality Assuarance of the NMRA is responsible for the analyzing of the quality of any medicine, medical device or borderline product forwarded by the Authority. It functions as an additional approved analyst when the circumstance so requires.
Find Out MorePharmacovigilance Division is responsible for monitoring and dealing with adverse drug reaction, quality failure and counterfeit medicines.
Find Out MoreInspectorate and Enforcement Division is responsible for inspecting and investigating issues pertaining to proper implementation of the provision of the NMRA Act.
Find Out MoreNational Medicines Regulatory Authority,
State Engineering Corporation Building (2nd Floor),
No. 130,
W.A.D Ramanayaka Mawatha,
Colombo 02,
Sri Lanka
Certificate of Analysis - New Format Update
The previous Certificate of Quality has been replaced with a revised new report format, which includes four copies printed in four different colours.
Click Here: Certificate of Analysis - New Format
This publicly accessible database provides official information on medicines recall and revocation notifications that are taken to remove unsafe / ineffective/ substandard medicines from the market. This database is continuously updated. Find the current updated version of the database as of 2025.10.14
Click Here : Medicines Recall and Revocation Database - Upto 14.10.2025
All Marketing Authorization Holders (MAHs) of medicines are hereby informed that the following categories of applications, which remain pending at the Pricing Division due to non-response from applicants within three months from the initial communication from the NMRA, will be considered for rejection from both the Pricing Review Process and the Registration Process at the NMRA:
· Applications where applicants have not submitted there quested price details.
· Applications where applicants have not responded to the MRP determinations officially communicated by the NMRA.
A notification letter will be issued to inform the withdrawal and closure of these applications and applicants can submit any concerns or clarifications regarding this decision within one month of this letter. Failure to respond within this period will result in the permanent rejection of your application by the NMRA.
Please note that, after rejection,if the applicants wish to proceed further, these product registration applications must be resubmitted as a new application to the NMRA.
This publicly accessible database provides official information on medicines recall and revocation notifications-taken to remove unsafe / ineffective / substandard medicines from the market. This initiative has taken as per the provisions of NMRA Act, No. 5 of 2015 and is implemented as recommended by the WHO Global Bencharking tool to achieve and maintain international standards for public health protection and supply chain intergity.
Click Here : Medicines Recall and Revocation Database. (since 2020)
